Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce O'Shaughnessy

Showing results (11-20 of 183) with videos related to

Pageof 19
Sort By:
Cancer Journal (Sudbury, Mass.)|November 26, 2013
Dendritic cells, inflammation, and breast cancerKarolina Palucka, Lisa M Coussens, Joyce O'Shaughnessy
JCO Oncology Practice|November 12, 2024
Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical ApproachJing Xi, Cynthia X Ma, Joyce O'Shaughnessy
Cancer Metastasis Reviews|March 30, 2016
Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastasesMinetta C Liu, Javier Cortés, Joyce O'Shaughnessy
Cancer Treatment Reviews|August 10, 2018
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancerJoyce O'Shaughnessy, J Thaddeus Beck, Melanie Royce
Clinical Breast Cancer|May 6, 2023
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease CharacteristicsJoyce O'Shaughnessy, William Gradishar, Ruth O'Regan, et al.
The Oncologist|November 28, 2002
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?Andrew D Seidman, Joyce O'Shaughnessy, Jean-Louis Misset
Breast Cancer Research and Treatment|April 9, 2013
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysisJoyce O'Shaughnessy, William J Gradishar, Paul Bhar, et al.
Genes & Diseases|September 28, 2018
Highlights of the 2015 San Antonio Breast Cancer SymposiumMark Keaton, Debu Tripathy, Joyce O'Shaughnessy, et al.
Clinical Breast Cancer|August 23, 2011
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancerRobert Leonard, Bryan T Hennessy, Joanne L Blum, et al.
Breast Cancer Research and Treatment|October 15, 2010
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot studyNicholas Robert, Lea Krekow, Chris Stokoe, et al.
Pageof 19

Showing results (11-20 of 183) with videos related to

Sort By:
Pageof 19
Cancer Journal (Sudbury, Mass.)|November 26, 2013
Dendritic cells, inflammation, and breast cancerKarolina Palucka, Lisa M Coussens, Joyce O'Shaughnessy
JCO Oncology Practice|November 12, 2024
Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical ApproachJing Xi, Cynthia X Ma, Joyce O'Shaughnessy
Cancer Metastasis Reviews|March 30, 2016
Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastasesMinetta C Liu, Javier Cortés, Joyce O'Shaughnessy
Cancer Treatment Reviews|August 10, 2018
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancerJoyce O'Shaughnessy, J Thaddeus Beck, Melanie Royce
Clinical Breast Cancer|May 6, 2023
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease CharacteristicsJoyce O'Shaughnessy, William Gradishar, Ruth O'Regan, et al.
The Oncologist|November 28, 2002
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?Andrew D Seidman, Joyce O'Shaughnessy, Jean-Louis Misset
Breast Cancer Research and Treatment|April 9, 2013
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysisJoyce O'Shaughnessy, William J Gradishar, Paul Bhar, et al.
Genes & Diseases|September 28, 2018
Highlights of the 2015 San Antonio Breast Cancer SymposiumMark Keaton, Debu Tripathy, Joyce O'Shaughnessy, et al.
Clinical Breast Cancer|August 23, 2011
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancerRobert Leonard, Bryan T Hennessy, Joanne L Blum, et al.
Breast Cancer Research and Treatment|October 15, 2010
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot studyNicholas Robert, Lea Krekow, Chris Stokoe, et al.
Pageof 19